944581-09-3

Basic information

• Product Name: 2-Bromo-imidazo[2,1-b]thiazole
• Synonyms: 2-Bromo-imidazo[2,1-b]thiazole
• CAS NO: 944581-09-3
• Molecular Formula: C5H3BrN2S
• Molecular Weight: 203.05972
• Mol File: 944581-09-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Bromo-imidazo[2,1-b]thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-imidazo[2,1-b]thiazole(944581-09-3)
• EPA Substance Registry System: 2-Bromo-imidazo[2,1-b]thiazole(944581-09-3)

Safety Data

• Hazardous Substances Data: 944581-09-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-imidazo[2,1-b]thiazole is a chemical compound with the molecular formula C5H3BrN2S. It is a heterocyclic compound containing a five-membered ring with atoms of nitrogen, sulfur, and bromine. This chemical has potential applications in the pharmaceutical industry as it is a key building block in the synthesis of various bioactive molecules. It is also used as a reagent in organic synthesis and can be employed in the preparation of drugs, agrochemicals, and materials. Additionally, 2-Bromo-imidazo[2,1-b]thiazole has been studied for its potential antiviral and anti-cancer properties, making it a compound of interest for medicinal chemistry research.

Upstream product

• 107-20-0 2-chloroethanal 
• 3034-22-8 5-bromo-2-aminothiazole 

Relevant articles and documents

Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria

A series of 5-aryl-2-amino-imidazothiadiazole (ITD) derivatives were identified by a phenotype-based high-throughput screening using a blood stage Plasmodium falciparum (Pf) growth inhibition assay. A lead optimization program focused on improving antiplasmodium potency, selectivity against human kinases, and absorption, distribution, metabolism, excretion, and toxicity properties and extended pharmacological profiles culminated in the identification of INE963 (1), which demonstrates potent cellular activity against Pf 3D7 (EC50 = 0.006 μM) and achieves “artemisinin-like” kill kinetics in vitro with a parasite clearance time of 1/2) across species. These properties suggest the significant potential for INE963 (1) to provide a curative therapy for uncomplicated malaria with short dosing regimens. For these reasons, INE963 (1) was progressed through GLP toxicology studies and is now undergoing Ph1 clinical trials.